Ping Tan
Impact in
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery
- Cancer Research top 10%
- Cancer, Lipids, and Metabolism
Papers in
-
- Cancer, Lipids, and Metabolism 6
- Oncology 17
- Inflammatory Biomarkers in Disease Prognosis 12
- Cancer Immunotherapy and Biomarkers 4
- Co-authors
- Kui Luo (5 shared papers)Hu Zhang (5 shared papers)Qiang Wei (41 shared papers)Zhongwei Gu (4 shared papers)Xiaohe Tian (2 shared papers)Haitao Ding (1 shared paper)Xuelei Ma (1 shared paper)Xiaoting Chen (3 shared papers)
- Journals
- Scientific Reports (6 papers)Asian Journal of Andrology (5 papers)Cancer Medicine (4 papers)Frontiers in Pharmacology (2 papers)Medicine (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Ping Tan
83 papers receiving 2.6k citations
Ping Tan's Hit Papers
Peers
Comparison fields: 5 of 127
- Biomaterials 432
- Cancer Research 285
- Oncology 369
- Molecular Medicine 69
- Biomedical Engineering 587
Countries citing papers authored by Ping Tan
This map shows the geographic impact of Ping Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping Tan more than expected).
Fields of papers citing papers by Ping Tan
This network shows the impact of papers produced by Ping Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping Tan. The network helps show where Ping Tan may publish in the future.
Co-authors
The 25 scholars most cited alongside Ping Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Preparation and application of pH-responsive drug delivery systems Hit paper breakdown → | 2022 | 483 |
| 2 | Artificial intelligence aids in development of nanomedicines for cancer management Hit paper breakdown → | 2023 | 199 |
| 3 | 2020 | 189 | |
| 4 | 2020 | 151 | |
| 5 | 2020 | 124 | |
| 6 | 2021 | 104 | |
| 7 | 2016 | 93 | |
| 8 | 2021 | 86 | |
| 9 | 2022 | 59 | |
| 10 | 2023 | 56 | |
| 11 | 2022 | 50 | |
| 12 | 2012 | 46 | |
| 13 | 2021 | 45 | |
| 14 | 2021 | 45 | |
| 15 | 2018 | 41 | |
| 16 | 2017 | 38 | |
| 17 | 2016 | 31 | |
| 18 | 2018 | 30 | |
| 19 | 2020 | 29 | |
| 20 | 2014 | 29 |
About Ping Tan
Ping Tan is a scholar working on Cancer Research, Oncology, Surgery, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 88 papers that have together received 2.6k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (15 papers), Inflammatory Biomarkers in Disease Prognosis (12 papers), Renal cell carcinoma treatment (6 papers), Cancer, Lipids, and Metabolism (6 papers), Epigenetics and DNA Methylation (5 papers), Nanoplatforms for cancer theranostics (5 papers), Prostate Cancer Treatment and Research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Biomaterials (432 citations), Cancer Research (285 citations), Oncology (369 citations), Molecular Medicine (69 citations) and Biomedical Engineering (587 citations). Ping Tan has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Kui Luo, Hu Zhang, Qiang Wei, Zhongwei Gu, Xiaohe Tian, Haitao Ding, Xuelei Ma, Xiaoting Chen, Lu Yang and Hang Xu. Their work appears in journals such as Scientific Reports, Asian Journal of Andrology, Cancer Medicine, Frontiers in Pharmacology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.